• Explore /
  • Poster
  • / Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).

Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC).

Abstract Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Shilpa Gupta , Girish S. Kulkarni , Andrea Necchi , Hema Kishore Dave , Ekta Kapadia , Qing Zhao , Ashish M. Kamat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02625961

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr TPS591)

DOI

10.1200/JCO.2023.41.6_suppl.TPS591

Abstract #

TPS591

Poster Bd #

P14

Abstract Disclosures

Similar Posters

First Author: Girish S. Kulkarni

First Author: Ashish M. Kamat

First Author: Arjun Vasant Balar

First Author: Ashish M. Kamat